Total
0
Shares
Starpharma (ASX:SPL) - CEO, Jackie Fairley
CEO, Jackie Fairley
Source: The Morning Bulletin
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Starpharma’s (SPL) SPL7013 drug shows a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants
  • These strains are classified variants of concern due to their increased transmissibility, increased severity and reduced effectiveness to vaccines
  • Testing was undertaken in the laboratory of virologist Professor Philippe Gallay at The Scripps Research Institute in the US
  • Starpharma will test the Delta and Kappa variants when virus availability permits
  • Starpharma is up 4.5 per cent on the market and shares are trading at $1.63 at 10:41 am AEST

Starpharma’s (SPL) SPL7013 drug has shown a reduction of more than 99.9 per cent against the Alpha, Beta and Gamma SARS-CoV-2 variants.

These strains are classified variants of concern by international public health authorities due to their increased transmissibility, increased severity and reduced effectiveness to current treatments and vaccines.

Testing of SPL7013 was undertaken in the laboratory of virologist Professor Philippe Gallay at The Scripps Research Institute in the US.

The study showed that within 30 seconds to one minute of exposure, SPL7013 achieved more than 99 per cent reduction against the Beta and Gamma variants and more than 99.9 per cent reduction within five minutes against the Alpha variant.

Starpharma will test the Delta and Kappa variants when virus availability permits.

“We are impressed with the rapid and potent virucidal and antiviral activity of SPL7013 and that it is highly active against the Alpha, Beta and Gamma SARS-CoV-2 variants of concern that have emerged and recently dominated the pandemic,” Professor Gallay said.

“It is particularly exciting to see a product with this level of virucidal activity, especially against these variants of concern that are much more transmissible than earlier SARS-CoV-2 strains.”

SPL7013 is a key component of Starpharma’s VIRALEZE nasal spray which works by slowing down the infection of host cells when applied to cells before and after exposure to the virus.

From there, it blocks the interaction between viral surface proteins and human cell receptor proteins.

“We are very pleased to see such potent and rapid virucidal activity of VIRALEZE against multiple SARS-CoV-2 variants of concern, Alpha, Beta and Gamma,” CEO Dr Jackie Fairley commented.

“These variants continue to spread across the globe and challenge efforts to control the COVID-19 pandemic.”

Starpharma was up 4.5 per cent on the market with shares trading at $1.63 at 10:41 am AEST.

SPL by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.